Page last updated: 2024-12-07
aphidicolin glycinate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
aphidicolin glycinate: DNA polymerase II inhibitor; RN given refers to(HCL(3R-(3alpha,4alpha,4aalpha,6abeta,8beta,9beta,11abeta,11bbeta)-isomer); RN for parent cpd without isomeric designation not avail 5/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 21883635 |
MeSH ID | M0186527 |
Synonyms (1)
Synonym |
---|
aphidicolin glycinate |
Research Excerpts
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
" We investigated the pharmacokinetics of aphidicolin in mice and examined its activity either alone or in combination with DDP in the DDP-sensitive M5076 (M5) murine reticular cell sarcoma as well as in a DDP-resistant subline (M5/DDP)." | ( Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cavalli, F; D'Incalci, M; Damia, G; Davoli, E; Sessa, C; Tagliabue, G; Zucchetti, M, 1992) | 0.28 |
" Thus, we evaluated AG in combination with cisplatin in an in vivo model of cisplatin refractory human ovarian cancer." | ( Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cysyk, R; Hamilton, TC; Harrison, SD; Moyer, JD; O'Dwyer, PJ; Plowman, J; Suffness, M, 1994) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (16.67%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |